Urol. praxi. 2020;21(1):11-13 | DOI: 10.36290/uro.2020.017

Current treatment management of non-metastatic castration-resistant prostate cancer

MUDr. Nikol Rušarová, MUDr. Hana Študentová, Ph.D.
Onkologická klinika Fakultní nemocnice Olomouc

Prostate cancer is the most common cancer that affects men (except of skin tumors). Although most cases of prostate cancer are diagnosed and treated at an early stage, some patients already have primary dissemination or metastatic spread during therapy. Current research has led to the expansion of the treatment armamentarium for patients with prostate cancer. Therapeutic options in patients with castration-resistant prostate cancer aim to prolong survival with minimal development of complications and with the highest possible quality of life.

Keywords: castration-resistant prostate cancer, apalutamid, enzalutamid.

Published: April 17, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rušarová N, Študentová H. Current treatment management of non-metastatic castration-resistant prostate cancer. Urol. praxi. 2020;21(1):11-13. doi: 10.36290/uro.2020.017.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297.
    2. Huggins C, Stevens J, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209-223. Go to original source...
    3. Mottet N, Bellmunt J, Briers E, et al. AU-ESTRO-SIOG Guidelines on Prostate Cancer. [cit. 2019-08-10]. Dostupné z: http://uroweb.org/wp-content/uploads/EAU-Guidelines - -Prostate-Cancer-2018.pdf.
    4. Virgo KS, Basch E, Loblaw DA, et al. Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 2017; JCO 1952-1964. Go to original source... Go to PubMed...
    5. Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 2918-2925. Go to original source... Go to PubMed...
    6. Joyce R, Fenton MA, Rode P, et al. High dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy. J Urol 1998; 159: 149-153. Go to original source... Go to PubMed...
    7. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Cur Opin Pharmacol 2008; 8: 440-448. Go to original source...
    8. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012; 72: 1494-1503. Go to original source... Go to PubMed...
    9. Smith MR, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med 2018; 378: 1408-1418. Go to original source... Go to PubMed...
    10. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-790. Go to original source... Go to PubMed...
    11. Fizazi K, Scher HI, Miller K, et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 2014; 15: 1147-1156. Go to original source... Go to PubMed...
    12. Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol 2017; 71: 151-154. Go to original source... Go to PubMed...
    13. Hussain M, Fizazi K, Saad F, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2018; 378: 2465-2474. Go to original source... Go to PubMed...
    14. Penson DF, Armstrong AJ, Concepcion R, et al. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. J Clin Oncol 2016; 34: 2098-2106. Go to original source... Go to PubMed...
    15. Crawford ED, Koo PJ, Shore N, et al. A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). J Urol 2019; 201: 682-692. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.